Western blot analysis of the expression of KIT-mediated signalling pathways in tumour tissues demonstrated that cabozantinib treatment also decreased p-KIT, p-STAT3, p-AKT, p-mTOR, and p-ERK1/2 expression levels in vivo (Fig. 6E). Here, MAPK3 is linked to neoplasm.